Scarica l'app Stockscreener
12.61
8.22%
-1.13
Dopo l'orario di chiusura:
12.86
0.25
+1.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.74
Aprire:
$13.64
Volume 24 ore:
419.35K
Relative Volume:
0.62
Capitalizzazione di mercato:
$358.41M
Reddito:
$42.35M
Utile/perdita netta:
$-78.67M
Rapporto P/E:
-4.4778
EPS:
-2.8161
Flusso di cassa netto:
$-63.18M
1 W Prestazione:
-13.98%
1M Prestazione:
-14.39%
6M Prestazione:
+50.84%
1 anno Prestazione:
-33.46%
Intervallo 1D:
$12.57
$13.75
Intervallo di 1 settimana:
$12.03
$15.04
Portata 52W:
$5.50
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
12.61 | 358.41M | 42.35M | -78.67M | -63.18M | -2.8161 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2026-03-18 | Iniziato | B. Riley Securities | Buy |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-10-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Downgrade | Citigroup | Buy → Neutral |
| 2025-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-28 | Iniziato | BTIG Research | Buy |
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
A trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares. - Stock Titan
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket - Benzinga
Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update - Kalkine Media
Morning ammonia was in the normal range during a rare-disease trial, even with more protein - Stock Titan
Arcturus Therapeutics (ARCT) Slips 2.11% to $14.38 as Shares Drift Toward Range SupportSupport Level Bounce - dars.gov.et
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT) - Seeking Alpha
About 10,000 people have a rare liver disorder. Arcturus will discuss an investigational treatment. - Stock Titan
Arcturus Therapeutics Holdings Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - Investing.com India
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - investing.com
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - Investing.com UK
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year By Investing.com - Investing.com Canada
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year - Investing.com
ARCT Stock Price, Quote & News - Syfe
Arcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT - MarketBeat
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (ARCT) Peer Comparison – Compare with Others - Value Research
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Why is Arcturus Therapeutics stock surging today? By Investing.com - Investing.com Canada
Arcturus Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Arcturus Therapeutics (ARCT) Drops 6% as Biotech Sector Headwinds IntensifyFibonacci Fan - dars.gov.et
Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium - TipRanks
Arcturus (ARCT) Results Check: EPS Clears the Reported Estimate; Market Response: Shares Finish 22.38% Up for the Current SessionEarnings Power Value - vinanet.vn
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back - Yahoo Finance
Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45Low Volatility Picks - vinanet.vn
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - TradingView
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - Yahoo Finance
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):